We recently compiled a list of the Cathie Wood’s Stock Portfolio: 2025 Stock Picks. In this article, we are going to take a ...

ARK Innovation portfolio metrics are strong, and the vehicle likely presents diversification benefits. Click here to read an ...

In the latest trading session, Cathie Wood's ARK ETFs continued to adjust their portfolios, with significant moves seen in both buying and selling across various sectors. The largest transaction for ...

The inducement grant consisted of time-based restricted stock units ("RSUs”) for 21,863 shares of Intellia's common stock, ...

Fintel reports that on February 3, 2025, HC Wainwright & Co. initiated coverage of CRISPR Therapeutics (NasdaqGM:CRSP) with a ...

Cathie Wood-led Ark Invest made significant trades involving CRSP, TXG, RBLX, ACHR, NU, ADYEY, ACCD, and AVAV.

PFG Investments LLC lifted its stake in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 9.9% in the 4th quarter, ...

Learn more about whether Catalyst Pharmaceuticals, Inc. or CRISPR Therapeutics AG is a better investment based on AAII's A+ ...

Leerink Partnrs boosted their FY2024 earnings per share (EPS) estimates for CRISPR Therapeutics in a note issued to investors ...

CRISPR Therapeutics AG (CRSP) closed at $43.42 in the latest trading session, marking a -1.83% move from the prior day. The stock trailed the S&P 500, which registered a daily loss of 0.29%.

Investors in CRISPR Therapeutics AG (Symbol: CRSP) saw new options become available today, for the March 7th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ...

Kennedy Jr. will di­vest his in­ter­ests in sev­er­al bio­phar­ma com­pa­nies, in­clud­ing CRISPR Ther­a­peu­tics and Drag­on­fly Ther­a­peu­tics, if con­firmed by the ...